pharmaceuticals: search

Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals

today announced that they have filed a lawsuit in U.S. District Court in Delaware against Mylan Pharmaceuticals, Inc. and its subsidiary, Mylan, Inc., and Barr Pharmaceuticals, Inc. and its subsidiary, Barr Laboratories, Inc., for infringement of Eurand's U.S. Patent Number 7,387,793. This patent claims extended-release formulations containing the muscle relaxant cyclobenzaprine, including AMRIX(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules) and expires February 26, 2025. The lawsuit is based upon Abbreviated New Drug Applications (ANDAs) filed by Mylan and Barr, each seeking U.S. Food and Drug Administration (FDA) approval for a generic equivalent of the 15 mg and 30 mg strengths of AMRIX to be sold in the United States. The Mylan ANDA alleges that the AMRIX patent will not be infringed by its manufacture, use or sale of th

Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals

FRAZER, Pa. and PHILADELPHIA, November 26, 2008 /PRNewswire-FirstCall/ -- Cephalon, Inc. and Eurand, Inc. today announced that they have filed a lawsuit in U.S. District Court in Delaware against Mylan Pharmaceuticals, Inc. and its subsidiary, Mylan, Inc., and Barr Pharmaceuticals, Inc. and its subsidiary, Barr Laboratories, Inc., for infringement of Eurand's U.S. Patent Number 7,387,793. This patent claims extended-release formulations containing the muscle relaxant cyclobenzaprine, including AMRIX(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules) and expires February 26, 2025.

Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals

The Healthcare Sales & Marketing Network(R): Sales & Marketing News, Information and Networking for Medical Devices, Pharmaceuticals and Biotechnology.

Othera Pharmaceuticals Announces First U.S. Patent Issued On New Class of Compounds to Treat AMD and Other Ophthalmic Diseases

EXTON, Pa.--(BUSINESS WIRE)--Oct 28, 2008 - Othera Pharmaceuticals, Inc., a specialty pharmaceuticals company focused on novel, patient-administered products for ophthalmic disease, has today announced the U.S. Patent and Trademark Office (PTO) issued to Othera the first patent covering a broad class of disubstituted hydroxylamine small molecules that target oxidative stress and inflammation pathways believed to be involved in age-related macular degeneration (AMD) and other diseases of the eye. U.S. Patent No. 7,442,711 covers several new chemical entities, including composition of matter and use of the company's lead product candidate, OT-551. David Joseph, Othera's Chairman and CEO, commented, "We are quite pleased that the PTO has issued this important patent to protect our OT-551 intellectual property estate.

Titan Pharmaceuticals updates on Probuphine patent application

Add our medical news to StumbleUpon - Titan Pharmaceuticals updates on Probuphine patent application Add our medical news to Facebook - Titan Pharmaceuticals updates on Probuphine patent application

Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists

Add our medical news to StumbleUpon - Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists Add our medical news to Facebook - Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists

AstraZeneca Settles US Pulmicort Respules Patent Litigation with Ivax Pharmaceuticals - Quick Facts

(RTTNews) - Tuesday, AstraZeneca plc (AZN, AZN.L) said it signed a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals Inc., a subsidiary of Teva Pharmaceuticals USA. The agreement settles the patent infringement litigation filed by AstraZeneca following Teva's submission to the United States Food & Drug Administration of an Abbreviated New Drug Application for a generic version of Pulmicort Respules.

Teva Announces Agreement on Allegra(R) Patent Challenge

today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva's and Barr's U.S. generic versions of Aventis Pharmaceuticals' Allegra(R) (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.

Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals

PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) and Eurand, Inc. (Nasdaq: EURX) today announced that they have filed a lawsuit in U.S. District Court in

Teva Announces Agreement on Allegra Patent Challenge

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva’s and Barr’s U.S. generic versions of Aventis Pharmaceuticals’ Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.

Teva Announces Agreement on Allegra® Patent Challenge

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva’s and Barr’s U.S. generic versions of Aventis Pharmaceuticals’ Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.

::: Teva Announces Agreement on Allegra Patent Challenge

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva’s and Barr’s U.S. generic versions of Aventis Pharmaceuticals’ Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.

Teva Announces Agreement on Allegra Patent Challenge

JERUSALEM--(Business Wire)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva’s and Barr’s U.S. generic versions of Aventis Pharmaceuticals’ Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005. The present agreement releases Barr and Teva for all past and future activities in connection with the U.

Teva Announces Agreement on Allegra Patent Challenge

JERUSALEM (Business Wire) -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva's and Barr's U.S. generic versions of Aventis Pharmaceuticals' Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.

Teva Announces Agreement on Allegra Patent Challenge

JERUSALEM - (Business Wire) Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva’s and Barr’s U.S. generic versions of Aventis Pharmaceuticals’ Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.

Teva Announces Agreement on Allegra® Patent Challenge

JERUSALEM--(BUSINESS WIRE)--November 19, 2008--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva’s and Barr’s U.S. generic versions of Aventis Pharmaceuticals’ Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.

Teva Announces Agreement on Allegra Patent Challenge

JERUSALEM--(BUSINESS WIRE)--Nov 19, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva's and Barr's U.S. generic versions of Aventis Pharmaceuticals' Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.

Salix Pharmaceuticals Ltd announces receipt of US Patent for rifaximin

Salix Pharmaceuticals Ltd (NASDAQ:SLXP), a developer and marketer of prescription pharmaceutical products for the treatment of gastrointestinal diseases, declared on 18 November the grant of US Patent No. 7,452,857 from the United States Patent and Trademark Office.

Inotek Pharmaceuticals granted two new US patents

Inotek Pharmaceuticals, a clinical-stage, drug-development company, has announced that the US Patent and Trademark Office has issued two new patents covering the company's two lead clinical compounds INO-8875 and INO-4885.

Inotek Pharmaceuticals Granted Two New US Patents

Inotek Pharmaceuticals, a clinical-stage, drug-development company, has announced that the US Patent and Trademark Office has issued two new patents covering the company's two lead clinical compounds INO-8875 and INO-4885.

Valeant Pharmaceuticals to Present at 2008 Credit Suisse Phoenix Health Care Conference

Valeant Pharmaceuticals International (VRX) today announced members of its senior management team will make a presentation at the 2008 Credit Suisse Phoenix Health Care Conference on Friday, November 14, 2008 at 9:30 a.m. MST. The conference will be held at the Arizona Biltmore Resort in Phoenix, Arizona.

Titan Pharmaceuticals Provides Update on Probuphine(R) Patent

Titan Pharmaceuticals, Inc. TTP today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company

Titan Pharmaceuticals Provides Update on Probuphine(R) Patent Application

Titan Pharmaceuticals, Inc. (TTP) today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company

Titan Pharmaceuticals Provides Update on Probuphine(R) Patent Application

Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company's method of use patent application for the use of Probuphine in the treatment of opioid addiction and chronic pain. Probuphine is Titan's novel, subcutaneous implant formulation in development that delivers six months of buprenorphine, and is presently covered by U.S. and European patents licensed from Massachusetts Institute of Technology with terms that expire in 2009 and 2010 respectively. This does not impact the expected data exclusivity protection following product approval of 3 years in the U.S. (Hatch- Waxman Act) and 10 years in Europe, although it may make partnering in the U.

Titan Pharmaceuticals Provides Update on Probuphine(R) Patent Application

Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company

Search took 0.04 seconds.